Novocure enrols first patient in Phase 3 TRIDENT study of Optune treatment
Novocure has enrolled the first patient in Phase 3 TRIDENT trial, evaluating Optune, a non-invasive, antimitotic cancer treatment, used concurrent with radiation therapy in newly diagnosed glioblastoma (GBM).